Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center

Trallero-Araguás, Ernesto; Gil‐Vila, Albert; Martínez-Gómez, Xavier; Pinal‐Fernandez, Iago; Alvarado-Cárdenas, Marcelo; Simó-Perdigó, M.; Selva-O’Callaghan, Albert

doi:10.1016/j.semarthrit.2021.12.008

Cited by 9 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After an adequate cancer-risk stratification of IIM patients, performing a PET/ CT scan at myositis onset seems to be an efficient approach to rule out CAM, with a high negative predictive value according to the experience of a Spanish tertiary centre (108). Machine learning algorithms can help identify anti-TIF1γ+ patients at higher cancer risk, with disease duration, neutrophil-to-lymphocyte ratio and CRP values as significant clinical parameters for recognising these patients (109).…”

Section: Antisynthetase Syndromementioning

confidence: 99%

Idiopathic inflammatory myopathies: one year in review 2022

Cardelli

Zanframundo

Cometi

et al. 2023

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders in which chronic inflammation of the skeletal muscle, leading to muscle weakness, is a common feature. Different phenotypes have been identified within the IIM spectrum based on extra-muscular manifestations, immunology, muscle histology, responsiveness to therapy, and prognosis. The pathogenesis, classification, treatment, and prognosis of the different IIM subtypes are subject to active discussion and research. This review highlights the most relevant literature published on this topic over the last year.

show abstract

Section: Antisynthetase Syndromementioning

confidence: 99%

Idiopathic inflammatory myopathies: one year in review 2022

Cardelli

Zanframundo

Cometi

et al. 2023

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

“…Furthermore, whether PET/CT offers any additional value compared with a routine battery of screening tests for neoplasm in IIM patients remains undefined. The studies that have explored this aspect showed a sensitivity and specificity of PET/CT of 66.7-94 and 80-97.8%, respectively [59][60][61][62].…”

Section: Pet/computed Tomographymentioning

confidence: 99%

Update on muscle imaging in myositis

Tan,

Di Matteo,

Wakefield

et al. 2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review Imaging techniques such as MRI, ultrasound and PET/computed tomography (CT) have roles in the detection, diagnosis and management of myositis or idiopathic inflammatory myopathy (IIM). Imaging research has also provided valuable knowledge in the understanding of the pathology of IIM. This review explores the latest advancements of these imaging modalities in IIM. Recent findings Recent advancements in imaging of IIM have seen a shift away from manual and qualitative analysis of the images. Quantitative MRI provides more objective, and potentially more sensitive characterization of fat infiltration and inflammation in muscles. In addition to B-mode ultrasound changes, shearwave elastography offers a new dimension to investigating IIM. PET/CT has the added advantage of including IIM-associated findings such as malignancies. Summary It is evident that MRI, ultrasound and PET/CT have important roles in myositis. Continued technological advancement and a quest for more sophisticated applications help drive innovation; this has especially been so of machine learning/deep learning using artificial intelligence and the developing promise of texture analysis.

show abstract

“…The database search identified 252 records found and 236 records were excluded after title/abstract screening and full-text content because those did not provide any relevant information on the topic of this review (Figure 1). Sixteen articles were eligible for a more detailed description in this review (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31).…”

Section: Literature Search Study and Patient Characteristicsmentioning

confidence: 99%

“…Four studies (16,24,27,31) specifically investigated the value of [ 18 F]FDG-PET/CT to identify occult malignancy in patients with inflammatory myopathies (IM). The main results are summarized in Table 2.…”

Section: [ 18 F]fdg-pet/ct and Cancer Diagnosismentioning

confidence: 99%

The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis

2022

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies (IIM) are considered systemic diseases involving different organs and some subtypes are associated with increased cancer risk. In this review, we provide a comprehensive summary of the current use and potential applications of (semi-)quantitative [18F]FDG-PET/CT indices in patients with IIM focusing on dermatomyositis and polymyositis. Visual interpretation and (semi-)quantitative [18F]FDG-PET indices have a good overall performance to detect muscle activity but objective, robust and standardized interpretation criteria are currently lacking. [18F]FDG-PET/CT is a suitable modality to screen for malignancy in patients with myositis and may be a promising tool to detect inflammatory lung activity and to early identify patients with rapidly progressive lung disease. The latter remains to be determined in large, prospective comparative trials.

show abstract

Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center

Cited by 9 publications

References 32 publications

Idiopathic inflammatory myopathies: one year in review 2022

Idiopathic inflammatory myopathies: one year in review 2022

Update on muscle imaging in myositis

The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis

Contact Info

Product

Resources

About